Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0WK0P
|
|||
| Former ID |
DIB009011
|
|||
| Drug Name |
Topiroxostat
|
|||
| Synonyms |
FYX-051; Xanthine oxidoreductase inhibitor (oral, gout), Fuji Yakuhin
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Gout [ICD-11: FA25; ICD-10: M10] | Phase 2 | [1] | |
| Company |
Fuji Yakuhin Kogyo Co Ltd
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C13H8N6
|
|||
| Canonical SMILES |
C1=CN=CC=C1C2=NC(=NN2)C3=CC(=NC=C3)C#N
|
|||
| InChI |
1S/C13H8N6/c14-8-11-7-10(3-6-16-11)13-17-12(18-19-13)9-1-4-15-5-2-9/h1-7H,(H,17,18,19)
|
|||
| InChIKey |
UBVZQGOVTLIHLH-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 577778-58-6
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Xanthine dehydrogenase/oxidase (XDH) | Target Info | Inhibitor | [2] |
| BioCyc | Purine nucleotides degradation | |||
| Urate biosynthesis/inosine 5'-phosphate degradation | ||||
| Guanosine nucleotides degradation | ||||
| Adenosine nucleotides degradation | ||||
| Retinoate biosynthesis II | ||||
| KEGG Pathway | Purine metabolism | |||
| Caffeine metabolism | ||||
| Drug metabolism - other enzymes | ||||
| Metabolic pathways | ||||
| Peroxisome | ||||
| Panther Pathway | Adenine and hypoxanthine salvage pathway | |||
| Purine metabolism | ||||
| Pathwhiz Pathway | Caffeine Metabolism | |||
| Purine Metabolism | ||||
| Reactome | Purine catabolism | |||
| WikiPathways | Oxidative Stress | |||
| Effects of Nitric Oxide | ||||
| Metabolism of nucleotides | ||||
| Selenium Micronutrient Network | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02327754) Effect of Topiroxostat on Urinary Albumin Excretion Early Stage Diabetic Nephropathy and Hyperuricemia With or Without Gout. U.S. National Institutes of Health. | |||
| REF 2 | QT/QTc study conducted in Japanese adult healthy subjects: a novel xanthine oxidase inhibitor topiroxostat was not associated with QT prolongation. J Clin Pharmacol. 2014 Apr;54(4):446-52. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.